Shareholders Fight Amgen's Stay Bid
A group of shareholders that claims Amgen Inc. misled investors by concealing the results of a clinical study involving two of its top-selling anemia drugs has challenged the biotech company's bid...To view the full article, register now.
Already a subscriber? Click here to view full article